Current therapeutic approaches for IBD, including aminosalicylates, corticosteroids, immunosuppressants, and biologic agents targeting cytokines like tumour necrosis factor-α (TNF-α), have improved disease management [9,10]. The gene discussed is TNF; the disease is inflammatory bowel disease.